SHL TELEMEDICINE LTD. Press release
Mayo Clinic Collaborates with SHL Telemedicine using SmartHeart™ Technology 12 lead ECG
Study intends to evaluate the use of home telemonitoring SmartHeart technology to decrease hospital visits and lower healthcare utilization costs
Tel Aviv / Zurich / Newton MA, 14 October 2020 - Mayo Clinic and SHL Telemedicine Ltd., today announced a collaboration to evaluate the incidence of emergency department visits, re-hospitalizations and MACE (major adverse cardiovascular events), and cost-effectiveness over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG, the golden standard ECG for diagnosing heart attack.
The central hypothesis is that the use of SmartHeart 12 lead ECG home telemonitoring by patients may decrease general and cardiac emergency department presentation and hospital readmission rates without an increase in MACE, and at a lower healthcare utilization cost compared to patients with standard therapy alone.
"We have seen the clinical benefits to patients as well as efficient use of healthcare resources by institutions using SHL's patented SmartHeart technology, and this collaboration presents an opportunity to broaden our knowledge in the U.S. market," said Erez Nachtomy, CEO of SHL Telemedicine. "We believe our SmartHeart technology could have important clinical implications for telemedicine and remote patient monitoring in the very near future. We are excited to work with Mayo Clinic."
For further information please contact:
Martin Meier-Pfister, IRF, Phone: +41 43 244 81 40, shl@irf-reputation.ch
| Provider | Channel | Contact | ||
|---|---|---|---|---|
|
EQS Group Ltd., Switzerland switzerland.eqs.com |
newsbox.ch www.newsbox.ch |
Provider/Channel related enquiries cs.switzerland@eqs.com +41 41 763 00 50 |
